LGALS3 and metabolic dysfunction-associated steatohepatitis: However, the most relevant indication regarding the role of Gal-3 in psoriasis was obtained unexpectedly during the exploratory phase 2 clinical trials on the use of GR-MD-02 in nonalcoholic steatohepatitis (“NASH”) (ClinicalTrials.gov Identifier: NCT01899859).